SCHEMBL24257811

SCHEMBL24257811

C=Cc1cnc(C(=O)NCC(=O)OCC)c(O)c1C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
EGLN1 Q9GZT9 4/20 0.40
MAPT P10636 1/20 0.40
VEGFA P15692 1/20 0.40
FLT1 P17948 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
GAA P10253 2/20 0.37
TP53 P04637 1/20 0.37
GLA P06280 1/20 0.37
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.36
PPID Q08752 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257725 0.90 ALDH1A1 (0.43) ALDH1A1LMNAHPGDHSD17B10SMN1; SMN2
SCHEMBL24257597 0.84 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHSD17B10SMN1; SMN2
SCHEMBL26260136 0.84 SMN1; SMN2 (0.45) ALDH1A1LMNAHPGDHSD17B10SMN1; SMN2
SCHEMBL24257754 0.81 EGLN1 (0.51) EGLN1VEGFAFLT1EGLN3GAA
SCHEMBL29248910 0.79 MEN1 (0.43) ALDH1A1HSD17B10SMN1; SMN2EGLN1NPC1
SCHEMBL30453195 0.76 CASP1 (0.49) ALDH1A1LMNAHPGDHSD17B10SMN1; SMN2
SCHEMBL24257727 0.76 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHSD17B10SMN1; SMN2
SCHEMBL24257534 0.76 CASP1 (0.49) ALDH1A1LMNAHPGDHSD17B10SMN1; SMN2
SCHEMBL24257569 0.75 EGLN1 (0.48) ALDH1A1HPGDEGLN1RAB9AGAA
SCHEMBL24257753 0.75 EGLN1 (0.48) EGLN1VEGFAFLT1EGLN3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ALDH1A1 1362/4885LMNA 4120/4885HPGD 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.